Dennis J. Purcell
Senior Managing Partner, Aisling Capital
Mr. Purcell has served as the Senior Managing Director of Aisling Capital since February 2000 and is responsible for the management of the Partnership. The fund has approximately $1.7 Billion of assets under management.
Prior to joining Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries.
During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP and honored as one of the top 50 Irish- American businessmen and cited as the top 100 contributors to the biotechnology industry. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
Mr. Purcell currently serves as a director of Paratek Pharmaceuticals, Inc., and Xanodyne Pharmaceuticals, Inc. Previously he served as a director of Aton Pharmaceuticals, Inc., Bridge Pharmaceuticals, Inc., Cengent Therapeutics, Inc., Dynova Laboratories, Inc., and Valentis, Inc.
He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association and the Irvington Institute. He also serves on the Board of L.E.K. consulting.
Mr. Purcell received his M.B.A. from Harvard University, and his B.S. in Accounting from the University of Delaware.